Guinea Pig Animal Model for Predicting Immunogenicity of Insulin Analogues

Abstract

Our goal is to employ the guinea pig animal model for assessing the immunogenicity of post-production recombinant insulin and three distinct insulin analogs: Glargine, Aspart, and Lispro. These insulin analogs have undergone structural modifications or alterations from the original insulin primary sequence to improve their pharmacokinetic and pharmacodynamic characteristics. This enhancement enables better management of blood glucose levels in individuals with diabetes. By conducting this study, we seek to determine whether commercially available insulin and its analogs carry a risk of eliciting an immune response in the form of antibodies. Any immune response can potentially reduce the effectiveness of the insulin analogs and lead to adverse effects. Moreover, we aim to evaluate the cross-reactivity of antibodies generated against these insulin analogs. This involves a focused investigation to determine if these antibodies exclusively bind to the modified epitope of the B chain in the analogs. Using the guinea pig animal model, we can gather valuable insights into the immunogenicity potential of insulin and its insulin analogs in humans. This information will contribute to our understanding of their safety and efficacy profiles, assisting in the development of improved insulin therapies for individuals with diabetes.